FindTrial
Sign In

Fx-1006A

DRUG5 trials

Sponsors

Pfizer

Conditions

ATTR-PNCardiomyopathyFamilial Amyloid PolyneuropathyMild Hepatic DysfunctionModerate Hepatic DysfunctionTransthyretin-associated Amyloidosis With Polyneuropathy

Phase 1

Pharmacokinetics Of Orally Administered Fx-1006A In Subjects With Hepatic Dysfunction
CompletedNCT01358565
PfizerMild Hepatic Dysfunction, Moderate Hepatic Dysfunction
Start: 2010-11-30End: 2011-04-30Updated: 2011-06-23

Phase 2

Safety and Efficacy Study of Fx-1006A in Patients With Familial Amyloidosis
CompletedNCT00409175
PfizerFamilial Amyloid Polyneuropathy
Start: 2007-01-31End: 2009-05-31Updated: 2012-12-17
The Effects of Fx-1006A on Transthyretin Stabilization and Clinical Outcome Measures in Patients With Non-V30M Transthyretin Amyloidosis
CompletedNCT00630864
PfizerTransthyretin-associated Amyloidosis With Polyneuropathy
Start: 2008-06-30End: 2010-01-31Updated: 2013-01-18
The Effects Of Fx-1006A On Transthyretin Stabilization And Clinical Outcome Measures In Patients With V122I Or Wild-Type TTR Amyloid Cardiomyopathy
CompletedNCT00694161
PfizerCardiomyopathy
Start: 2008-08-31End: 2010-01-31Updated: 2013-01-11
An Extension of Study Fx-005 Evaluating Long-Term Safety And Clinical Outcomes Of Fx-1006A In Patients With Transthyretin Amyloid Polyneuropathy
CompletedNCT00791492
PfizerATTR-PN, Familial Amyloid Polyneuropathy
Start: 2008-07-31End: 2010-10-31Updated: 2012-12-17

Related Papers

Evaluation of Mortality During Long-Term Treatment with Tafamidis for Transthyretin Amyloidosis with Polyneuropathy: Clinical Trial Results up to 8.5 Years
Neurology and Therapy2020-02-2729 citations
A comprehensive safety profile of tafamidis in patients with transthyretin amyloid polyneuropathy
Amyloid2019-07-2729 citations
Influence of baseline neurologic severity on disease progression and the associated disease-modifying effects of tafamidis in patients with transthyretin amyloid polyneuropathy
Orphanet Journal of Rare Diseases2018-12-0118 citations
Tafamidis delays disease progression in patients with early stage transthyretin familial amyloid polyneuropathy: additional supportive analyses from the pivotal trial
Amyloid2017-01-0258 citations
Treatment With Tafamidis Slows Disease Progression in Early-Stage Transthyretin Cardiomyopathy
Clinical Medicine Insights Cardiology2017-01-0138 citations
Early intervention with tafamidis provides long-term (5.5-year) delay of neurologic progression in transthyretin hereditary amyloid polyneuropathy
Amyloid2016-07-02101 citations
Tafamidis in Transthyretin Amyloid Cardiomyopathy
Circulation Heart Failure2015-04-15134 citations